Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALXN1920 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALXN1920 | EXPERIMENTAL | Participants will receive ALXN1920 subcutaneous (SC) and background treatment of ACE/ARB and Rituximab. |
| Placebo | EXPERIMENTAL | Participants will receive placebo subcutaneous (SC) and background treatment of ACE/ARB and Rituximab. |
| Name | Type | Description |
|---|---|---|
| ALXN1920 | DRUG | Participants will receive ALXN1920 SC infusion. |
| Placebo | DRUG | Participants will receive Placebo SC infusion. |
Inclusion Criteria: * Participants who have a documented diagnosis of PMN, established by positive antiPLA2R antibody level (\> 20 RU/mL) at Screening, which must be confirmed by a central laboratory * Participants are willing to receive the background Standard of Care (SoC) * Participants at high ...
ALXN1920 is an investigational small molecule being developed for the treatment of primary membranous nephropathy (PMN), a kidney disorder. It is currently in Phase 2 clinical development and is not yet approved for any indication. The Phase 2 study is enrolling adults aged 18 years and older with PMN.
ALXN1920 is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the ongoing Phase 2 clinical trial evaluating the drug in primary membranous nephropathy.
ALXN1920 is in Phase 2 clinical development. The only registered trial for this drug is a Phase 2 study that is currently recruiting participants. There are no completed trials for ALXN1920, and it has not been approved by the FDA or any other regulatory agency.
ALXN1920 is being evaluated in one clinical trial: NCT07157787, titled "Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)." This Phase 2 trial is recruiting and plans to enroll 30 adult participants across sites in the United States, Argentina, Australia, Brazil, China, France, Italy, Spain, Taiwan, and the United Kingdom.
No, ALXN1920 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for primary membranous nephropathy. The ongoing Phase 2 trial, NCT07157787, is still recruiting participants, and no regulatory approvals have been granted for this asset.